Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01861249 · ClinicalTrials.gov registry record · Phase 2
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01861249 is a Phase 2 study that was terminated before completion, run by Sanofi. The registered enrollment target is 6 participants.
The verdict
NCT01861249, a Phase 2 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Primary Objective: To assess the long term safety and tolerability of SAR339658 Secondary Objective: To assess the long term efficacy of SAR339658
Interventions
- DRUG SAR339658
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01861249
The ClinicalTrials.gov registry entry for NCT01861249 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAR339658 is the first listed.
NCT01861249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01861249 about?
NCT01861249 is a clinical study titled "Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)". Primary Objective: To assess the long term safety and tolerability of SAR339658 Secondary Objective: To assess the long term efficacy of SAR339658
What is the current status of trial NCT01861249?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2013-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01861249?
The interventions under investigation include: SAR339658 (DRUG).
Who is sponsoring clinical trial NCT01861249?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.